{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Receptors+Chimeric+Antigen&page=5", "query": { "condition": "Receptors Chimeric Antigen", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 377, "total_pages": 38, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Receptors+Chimeric+Antigen&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Receptors+Chimeric+Antigen&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-11T12:34:03.515Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04003649", "title": "IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Glioblastoma", "Refractory Glioblastoma" ], "interventions": [ { "name": "IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2019-12-02", "completion_date": "2026-09-26", "has_results": false, "last_update_posted_date": "2026-05-14", "last_synced_at": "2026-10-11T12:34:03.515Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04003649" }, { "nct_id": "NCT02650414", "title": "CD22 Redirected Autologous T Cells for ALL", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "B Cell Leukemias", "B Cell Lymphomas" ], "interventions": [ { "name": "Cohort 1", "type": "BIOLOGICAL" }, { "name": "Cohorts 2", "type": "BIOLOGICAL" }, { "name": "Cohort 3", "type": "BIOLOGICAL" }, { "name": "Cohort 3A", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "29 Years", "sex": "ALL", "summary": "1 Year to 29 Years" }, "enrollment_count": 41, "start_date": "2016-01-13", "completion_date": "2037-12", "has_results": false, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-10-11T12:34:03.515Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02650414" }, { "nct_id": "NCT02631044", "title": "Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Hodgkin Lymphoma", "Diffuse Large B Cell Lymphoma", "Follicular Lymphoma", "Mantle-cell Lymphoma", "Primary Mediastinal B-cell Lymphoma" ], "interventions": [ { "name": "JCAR017 (lisocabtagene maraleucel) single-dose schedule", "type": "BIOLOGICAL" }, { "name": "JCAR017 (lisocabtagene maraleucel) 2-dose schedule", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Juno Therapeutics, a Subsidiary of Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 387, "start_date": "2016-01-06", "completion_date": "2024-05-16", "has_results": false, "last_update_posted_date": "2024-06-27", "last_synced_at": "2026-10-11T12:34:03.515Z", "location_count": 14, "location_summary": "Birmingham, Alabama • Duarte, California • San Francisco, California + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02631044" }, { "nct_id": "NCT06703216", "title": "Pre-emptive Anakinra for Cytokine Event Reduction", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "B-Acute Lymphoblastic Leukemia", "CAR-T Cell Therapy", "Cytokine Release Syndrome", "Immune Effector Cell Associated Neurotoxicity Syndrome", "Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome" ], "interventions": [ { "name": "Anakinra (Kineret®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kevin McNerney", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "25 Years", "sex": "ALL", "summary": "1 Year to 25 Years" }, "enrollment_count": 0, "start_date": "2026-10", "completion_date": "2030-02-28", "has_results": false, "last_update_posted_date": "2026-08-13", "last_synced_at": "2026-10-11T12:34:03.515Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06703216" }, { "nct_id": "NCT02746952", "title": "Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "B-cell Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "UCART19", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Institut de Recherches Internationales Servier", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "69 Years", "sex": "ALL", "summary": "16 Years to 69 Years" }, "enrollment_count": 25, "start_date": "2016-08-01", "completion_date": "2020-07-28", "has_results": false, "last_update_posted_date": "2021-10-01", "last_synced_at": "2026-10-11T12:34:03.515Z", "location_count": 3, "location_summary": "Boston, Massachusetts • Philadelphia, Pennsylvania • Houston, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02746952" }, { "nct_id": "NCT00881920", "title": "Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma", "Myeloma", "Leukemia" ], "interventions": [ { "name": "Kappa CD28 T cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2009-07", "completion_date": "2035-07", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-11T12:34:03.515Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00881920" }, { "nct_id": "NCT05634785", "title": "CD30 CAR for CD30+ NSGCT", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Germ Cell Tumor", "Nonseminomatous Germ Cell Tumor" ], "interventions": [ { "name": "ATLCAR.CD30 Cells", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamid", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2022-12-09", "completion_date": "2025-12-18", "has_results": false, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-10-11T12:34:03.515Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05634785" }, { "nct_id": "NCT05416554", "title": "Long-term Cognitive, Neuropsychiatric and Functional Outcomes in Adults Who Have Received Chimeric Antigen-Receptor T-Cell (CAR-T) Therapy for Aggressive Lymphoma at Stanford", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Non Hodgkin Lymphoma" ], "interventions": [ { "name": "Neuropsychological testing", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2025-12", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-06-24", "last_synced_at": "2026-10-11T12:34:03.515Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05416554" }, { "nct_id": "NCT06964737", "title": "Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Malignant Glioma", "Recurrent WHO Grade 3 Glioma", "Recurrent WHO Grade 4 Glioma", "WHO Grade 2 Glioma", "WHO Grade 3 Glioma", "WHO Grade 4 Glioma" ], "interventions": [ { "name": "Anti-GARP Chimeric Antigen Receptor-T Cells", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Chest Radiography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Pheresis", "type": "PROCEDURE" }, { "name": "Surgical Procedure", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2025-05-21", "completion_date": "2027-05-31", "has_results": false, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-10-11T12:34:03.515Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06964737" }, { "nct_id": "NCT06897930", "title": "A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lupus Erythematosus, Systemic" ], "interventions": [ { "name": "AZD0120", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 150, "start_date": "2025-04-21", "completion_date": "2029-05-01", "has_results": false, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-10-11T12:34:03.515Z", "location_count": 16, "location_summary": "San Francisco, California • Stanford, California • Tampa, Florida + 12 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06897930" } ] }